What is RedShiftBio?
RedShiftBio® is at the forefront of providing advanced analytical instrumentation tailored for the research, development, and manufacturing of protein therapeutic drugs. The company's proprietary Microfluidic Modulation Spectroscopy (MMS) technology offers a novel approach to directly probe the biophysical structure of proteins. This patented MMS technology delivers comprehensive secondary structure information through five key measurements in a single, automated analysis. This capability aims to streamline and enhance the drug development process by reducing the reliance on multiple, disparate instruments, thereby accelerating the path from discovery to market.
How much funding has RedShiftBio raised?
RedShiftBio has raised a total of $71.7M across 9 funding rounds:
Series B
$6.2M
Private Equity
$2.4M
Private Equity
$751K
Private Equity
$1M
Series C
$11M
Series D
$18M
Debt
$350K
Series E
$20M
Series B (2008): $6.2M led by InterWest Partners, Emerson Ventures, Alta California Partners, and Technology Venture Partners
Private Equity (2012): $2.4M, investors not publicly disclosed
Private Equity (2014): $751K featuring Technology Venture Partners, LLC
Private Equity (2015): $998K, investors not publicly disclosed
Series C (2017): $11M with participation from Technology Venture Partners and Waters
Series D (2020): $18M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series E (2021): $20M featuring Illumina Ventures, Waters, and Technology Venture Partners
Key Investors in RedShiftBio
Illumina Ventures
Illumina Ventures is a prominent venture capital firm specializing in genomics and precision health, aiming to foster innovation in life sciences and biopharmaceutical development.
Waters
Waters Corporation provides analytical instruments and software solutions that are critical for ensuring the safety and quality of medicines, food, and water, supporting scientific insights across global laboratories.
Technology Venture Partners
Technology Venture Partners is a growth-equity investment firm dedicated to accelerating technology companies by providing financial expertise and strategic guidance to drive market leadership.
What's next for RedShiftBio?
With the infusion of $20M in its latest strategic investment, RedShiftBio is poised to further accelerate its product development and market expansion. The company's focus on enhancing the analysis of protein therapeutics aligns with the growing demand for biologics in the pharmaceutical industry. Future endeavors will likely involve scaling manufacturing capabilities, expanding its sales and support infrastructure, and potentially exploring new applications for its MMS technology. The consistent backing from investors like Technology Venture Partners and Illumina Ventures suggests a strategic roadmap focused on innovation and market leadership in biophysical analysis.
See full RedShiftBio company page
